How were Zelira Therapeutics' earnings last quarter?

Zelira Therapeutics Limited (ASX:ZLD) posted its earnings results on Friday, February, 22nd. The company reported $0.00 earnings per share for the quarter.

What other stocks do shareholders of Zelira Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zelira Therapeutics investors own include Saputo (SAP) , Western Union (WU) , Intuitive Surgical (ISRG) and Heat Biologics (HTBX) .

ASX:ZLD

Zelira Therapeutics (ZLD) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free ZLD Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 311,821 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: 8.62%
Price Target: N/A

Stock Analysis

Get Zelira Therapeutics alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Zelira Therapeutics

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

ZLD Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive ZLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zelira Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2019
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:ZLD
CUSIP: N/A
CIK: N/A
Web: www.zeldatherapeutics.com
Phone: 61 8 6558 0886
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($3.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,430,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -242.94%
Return on Assets: -17.89%

Debt

Debt-to-Equity Ratio: 1.38
Current Ratio: 0.43
Quick Ratio: 1.85

Sales & Book Value

Annual Sales: $1.54 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 23.00
Book Value: A($0.21) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 11,350,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.52

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Osagie O. Imasogie Esq. (Age 62)
Founder & Chairman
Comp: $144k
Dr. Oludare Odumosu
MD, Global CEO & Director
Mr. Greg Blake
Executive Director
Mr. Timothy Ryan Slate
Company Secretary & Non-Executive Director
Mr. Rahul Ganesan
Vice President of Finance & Accounting
Dr. Patty Washer
Clinical Trial Consultant

Key Competitors

View All Competitors

Insiders

ZLD Stock Analysis - Frequently Asked Questions

How were Zelira Therapeutics' earnings last quarter?: Zelira Therapeutics Limited (ASX:ZLD) posted its earnings results on Friday, February, 22nd. The company reported $0.00 earnings per share for the quarter.
What other stocks do shareholders of Zelira Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zelira Therapeutics investors own include Saputo (SAP), Western Union (WU), Intuitive Surgical (ISRG) and Heat Biologics (HTBX).

This page (ASX:ZLD) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial